Biogen’s statement on the SMC decision
Biogen’s statement re. Scottish decision on nusinersen availability
UK campaign for access to treatments and support for those with spinal muscular atrophy
BLOG ARCHIVE
Breaking news: Scotland refuses to treat majority of people with spinal muscular atrophy
Scotland annouces very restricted access to Spinraza, depriving the majority of SMA patients of an effective treatment
Australia will allocate $240 million to fund Spinraza treatment
Australia will allocate 240 million Australian dollars to fund the break-through Spinraza treatment for those with spinal muscular atrophy.
Breaking news: Scotland refuses to treat majority of people with spinal muscular atrophy
Scotland annouces very restricted access to Spinraza, depriving the majority of SMA patients of an effective treatment
Australia will allocate $240 million to fund Spinraza treatment
Australia will allocate 240 million Australian dollars to fund the break-through Spinraza treatment for those with spinal muscular atrophy.
Update on Spinraza appraisal process
Update on the regulatory appraisal process of Spinraza in England and Wales
Update on Spinraza appraisal process
Update on the regulatory appraisal process of Spinraza in England and Wales
TreatSMA is looking for a trustee
TreatSMA is looking for a trustee!
TreatSMA is looking for a trustee
TreatSMA is looking for a trustee!